The
global Induced
Pluripotent Stem Cells Market size is expected to reach USD 3.09
billion by 2030 and is expected to expand at a CAGR of 10.61% from 2023 to
2030, according to a new report by Grand View Research, Inc. The market for
induced pluripotent stem cells (iPSC) is expanding quickly. The ability of
induced pluripotent stem cells to generate any cell or tissue essential by the
body to fight or combat illnesses such as leukemia, spinal cord injury,
cardiovascular disease, and diabetes is the primary reason for their
utilization.
Other
factors driving market expansion include higher research funding, an increase
in the number of genomics initiatives, and a surge in the application of genome
engineering in personalized drugs. This has accelerated the adoption of iPSC,
resulting in the market's profitable revenue growth. For instance, in October
2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic
partnership to advance the drug discovery process. Through the use of the most
cutting-edge drug discovery techniques to enable target evaluation, High-Throughput
Screening (HTS), & High-Content Screening, the partnership will give
drug development researchers along with scientists access to an integrative
platform of hiPSC-based assays.
Investments
in healthcare development and research have expanded significantly in recent
years, and this trend is projected to have a significant impact on induced
pluripotent stem cell demand over the forecast period. The expanding spectrum
of human iPSC cell lines' applications in precision medicine and the growing
emphasis on stem cell therapeutic applications are predicted to be
important factors driving induced pluripotent stem cell market expansion. For
instance, in March 2021, Sana Biotechnology, Inc. received authorization to use
FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially
available cell therapies, according to a joint statement from both companies.
Cell therapies can improve, fix, or substitute human biology, including cells,
tissues, and organs.
The
rise in research activity during the COVID-19 pandemic also enhanced iPSC-based
research. In addition, scientists' ongoing efforts to discover novel therapies
and treatments to manage the SARS CoV-2 infection have increased the need for
iPSCs as research tools. Furthermore, induced pluripotent stem cells can create
organoids or organ models that are physiologically equivalent, thus they can be
utilized to study the pathophysiology of viral infection in humans. Thus,
propelling the industry growth.
Furthermore,
the government and commercial sectors are expanding funding along with growing
industry that focuses on various scientific activities linked to iPSCs, and
people are becoming more aware of stem cells through various organizations.
However, challenges such as the high cost of cell reprograming, ethical
concerns, and lengthy processes are inhibiting the growth of the induced
pluripotent stem cell industry to a certain extend Moreover, low efficiency,
potential tumor risk, and insufficient programming are other concerns
restricting the expansion of the iPSC market.
List of Key Players in the Induced Pluripotent Stem Cells
Market
- STEMCELL
Technologies Inc.
- Cellular
Engineering Technologies Inc.
- REPROCELL
Inc.
- Takara Bio,
Inc.
- Axol
Bioscience Ltd.
- Fate
Therapeutics, Inc.
- FUJIFILM
Cellular Dynamics,
Inc.
- Cynata
Therapeutics Limited
- Evotec
SE
- Astellas
Pharma Inc.
Related Press
Release@ Induced
Pluripotent Stem Cells Market Report
Induced Pluripotent Stem Cells Market Report highlights
- By derived
cell type, the fibroblasts segment accounted for the largest share of
30.48% in 2022. The growing preference among healthcare professionals for
fibroblast as potential treatments for skin problems are propelling the
segment growth.
- By
application, the drug developmentsegment accounted for the largest share
of 49.09% in 2022. The prevalence of chronic diseases, sedentary
lifestyle, and others increase the demand for personalized therapies, and
the increasing interest of pharma & biotech companies to develop drugs
with the help of iPS cells promotes the industry growth.
- By end-user,
the pharmaceutical & biotechnology companies segment accounted for the
largest share of 59.77% in 2022. This segment is projected to dominate the
market since they make and develop various stem cell products
& technology for various diseases employing induced pluripotent
stem cells.
- North
America held the larger share of 42.36% in 2022. This is mostly due to
increased use of innovative systems and technologies in drug research,
toxicity testing, and disease modeling, as well as the region's growing
acceptance of stem cell therapies are the major reasons for driving the
market.
Induced Pluripotent Stem Cells
Market Report Scope
|
Report Attribute |
Details |
|
Market
size value in 2023 |
USD 1.52
billion |
|
Revenue
forecast in 2030 |
USD 3.09
billion |
|
Growth
rate |
CAGR of
10.61% from 2023 to 2030 |
|
Base year
for estimation |
2022 |
|
Historical data |
2018 - 2021 |
|
Forecast period |
2023 - 2030 |
Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/455568/rfc
Induced Pluripotent Stem Cells Market Segmentation
Grand
view research has segmented the global induced pluripotent stem cells market based
on derived cell type, application, end-user, and region:
Induced Pluripotent Stem Cells Derived Cell Type Outlook
(Revenue, USD Million, 2018 - 2030)
- Hepatocytes
- Fibroblasts
- Keratinocytes
- Amniotic
Cells
- Others
Induced Pluripotent Stem Cells Application Outlook
(Revenue, USD Million, 2018 - 2030)
- Drug
Development
- Tissue
Engineering & Regenerative
Medicine
- Neurology
- Orthopedics
- Oncology
- Cardiovascular
and Myocardial Infraction
- Diabetes
- Others
- Toxicology
Research
- Disease Modeling
Induced Pluripotent Stem Cells End-user Outlook (Revenue,
USD Million, 2018 - 2030)
- Academic
& Research Institutes
- Pharmaceutical
& Biotechnology Companies
- Others
Induced Pluripotent Stem Cells Regional Outlook (Revenue,
USD Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment